Provided by Tiger Trade Technology Pte. Ltd.

Camp4 Therapeutics Corp.

4.30
-0.1800-4.02%
Volume:40.36K
Turnover:177.28K
Market Cap:269.84M
PE:-1.93
High:4.52
Open:4.46
Low:4.26
Close:4.48
52wk High:7.75
52wk Low:1.41
Shares:62.75M
Float Shares:37.87M
Volume Ratio:0.20
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2250
EPS(LYR):-2.6500
ROE:-545.85%
ROA:-45.25%
PB:-389.38
PE(LYR):-1.62

Loading ...

Camp4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 22

CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy

TIPRANKS
·
May 14

CAMP4 Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Piper Sandler Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)

TIPRANKS
·
May 08

Analysts Offer Insights on Healthcare Companies: Warby Parker (WRBY), Omada Health, Inc. (OMDA) and CAMP4 Therapeutics Corporation (CAMP)

TIPRANKS
·
May 08

CAMP4 Therapeutics Corp expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
May 08

CAMP4 Therapeutics Q1 profit misses estimates, net loss widens

Reuters
·
May 08

Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate

Benzinga Earnings
·
May 08

Camp4 Q1 FY26 net loss widens to $18.3 million

Reuters
·
May 08

Camp4 Therapeutics Corp Q1 Income From Operations USD -13.071 Million

THOMSON REUTERS
·
May 08

Camp4 expects SYNGAP1 therapy CMP-002 to enter Phase 1/2 trial in H2 2026

Reuters
·
Apr 28

Fulcrum Therapeutics Inc - on April 23, Terminated License Agreement Dated July 5, 2023 With Camp4 - SEC Filing

THOMSON REUTERS
·
Apr 27

Camp4 Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 23

BRIEF-Camp4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 18

Camp4 grants inducement stock options for 43,000 shares at $4.59 each

Reuters
·
Apr 18

GOODYEAR ELEVATES 3RD ANNUAL DREAM SUMMER CAMP PROGRAM IN YUNNAN

prnewswire
·
Apr 17

Canadian GoldCamps Moves Ahead with Québec Gold Projects and NI 43-101 Work

TIPRANKS
·
Apr 15

CAMP4 Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Apr 14

Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Apr 14

Camp4 Therapeutics files Form 3 for director Michael F. MacLean

Reuters
·
Apr 04